Ask AI
HER2+ mBC Decision Support Tool
Interactive Decision Support Tool: Expert Treatment Guidance for HER2-Positive Metastatic Breast Cancer

Released: July 24, 2025

Instructions

This Interactive Decision Support Tool provides systemic treatment recommendations for patients with HER2-positive metastatic breast cancer from 5 experts based on the specific patient and disease characteristics you enter in the tool. It is recommended that you have as much information as possible available before you begin.

You will be prompted to provide specific information about your patient including prior receipt of adjuvant or neoadjuvant therapy for locally advanced disease, previous treatment(s) for metastatic or systemic disease, hormone receptor status.

Click on your selections. Your choices can be changed at any time simply by selecting the [change] icon by the question you want to change and entering a new choice.

Additional information on each variable/characteristic and why it is important for making management decisions is available by clicking on the [i] icon after each selection.

When all patient characteristics are entered, you will be asked to select the management option you are currently planning. Once that information is entered, you can click on Submit Patient Case to view the expert recommendations.

After reviewing your case-specific recommendations, you will be asked brief questions about how the recommendations influenced your decision-making. You will then be able to enter a new case scenario by clicking the Start New Case button.

Additional sections appear in the table of contents menu that provide more information about this tool: About This Tool, Instructions, and References.

When viewing the tool on the CCO website, you will also have the following options:

You will also be able to print/download the recommendations along with a summary of the patient characteristics and selected therapy you entered by clicking the Case Summary button.

Note: The current tool was developed in July 2025 and reflects the expert recommendations at that time.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Treatment Guidance for HER2-Positive Metastatic Breast Cancer” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal systemic treatment selection for patients with HER2-positive metastatic breast cancer. The information provided in the tool is based on the latest guideline recommendations and expert guidance of Shipra Gandhi, MD, MS; Reshma Mahtani, DO; Laura Spring, MD; Erica L. Mayer, MD, MPH, FASCO; and Heather McArthur, MD, MPH, FASCO.

The material published by Clinical Care Options (CCO) reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: Expert Treatment Guidance for HER2-Positive Metastatic Breast Cancer” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. CCO provides this information on an as-is basis. This disclaimer applies to all material published by CCO including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2025 Clinical Care Options, LLC. All rights reserved.

Program Content